Tuberculosis (TB), one of the top ten causes of death in the world, remains a significant global health challenge: it infected an estimated 10 million people and caused over 1.4 million deaths in 2019 [1]. The End TB Strategy of WHO of 2014 proposes to achieve zero death and suffering from TB by 2035 [2]. However, with a slowly declining incidence, the whole world is still far from this goal [1].Diabetes mellitus (DM), a non-communicable disease, is also a significant public health problem. The links between TB and DM drew intense attention in the past few years. A systematic review showed that the prevalence of DM among TB patients is high, ranging from 1.9% to 35% [3]. Studies have indicated that in some low-and middle-income countries with high TB prevalence, the incidence of diabetes is expected to rise drastically [4]. Strong evidence has proved the association between these two diseases [5]. For patients with active TB, DM can lead to poor TB treatment outcomes, a higher chance of relapse, and an increased risk of death, along with other unwanted consequences, such as TB drugresistance and TB multidrug-resistance [6].